Cas 204656-20-2 98% Liraglutide Powder GLP-1 Analogs Penicillin Bottle Packing

Cas 204656-20-2 98% Liraglutide Powder GLP-1 Analogs Penicillin Bottle Packing

What is Liraglutide?

The lalu peptide is a kind of acylation glucagon man peptide 1 (glp-1) receptor agonist. When elevated plasma glucose concentration, the lalu peptides can increase the cell inner phosphorus adenosine (CAMP), leading to insulin release, reduce blood sugar; When blood sugar levels drop and returns to normal, reduce insulin secretion.

Function

Liraglutide is a GLP-1 analogue that shares 97% sequence homology with human GLP-1, which binds to and activates the GLP-1 receptor. GLP-1 receptor is the target of natural GLP-1, an endogenous insulin stimulating hormone that promotes glucose-concentration-dependent insulin secretion by pancreatic beta cells. Unlike Dauran GLP-1, liraglutide's pharmacokinetic and pharmacokinetic characteristics in humans are suitable for a once-daily administration regimen. The mechanism of prolonged action after subcutaneous injection includes: autoconjugation which slows down absorption; Binding to albumin; Higher enzymatic stability to dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP), resulting in a longer plasma half-life.

Applicable to use metformin or sulfonylureas maximum tolerated dose treatment patients with poor blood sugar control still, with metformin or sulfonylureas in combination with the application.